Eli Lilly and Company (LLY)
Eli Lilly shares tumble on disappointing weight loss drug trial data
Eli Lilly and Co (NYSE:LLY) shares fell more than 10% at the market open as disappointing late-stage trial data for the company's oral weight loss drug orforglipron drew focus from strong second quarter earnings and raised full-year guidance. The trial showed orforglipron users saw an average weight loss of 12.4% over 72 weeks, which was positive and met the primary endpoint.
Eli Lilly (LLY) Q2 Earnings and Revenues Surpass Estimates
Eli Lilly (LLY) came out with quarterly earnings of $6.31 per share, beating the Zacks Consensus Estimate of $5.61 per share. This compares to earnings of $3.92 per share a year ago.
Eli Lilly's oral weight-loss pill didn't work so well, and the stock is plunging
Stock was heading for biggest one-day selloff in 26 years
Eli Lilly raises full-year profit forecast on weight-loss drug strength
Eli Lilly raised its full-year profit forecast on Thursday, betting on surging demand for its blockbuster weight-loss drug, Zepbound, as it targets new markets and looks to grab more share from Novo Nordisk's Wegovy.
Novo Nordisk Stock Catches a Downgrade. The Eli Lilly Threat Is Just One Reason.
Novo Nordisk stock was downgraded to Neutral from Buy by UBS analysts, who cited the threat posed by its U.S. rival.
Eli Lilly: Sell LLY Stock Ahead of Its Earnings?
Eli Lilly (NYSE:LLY) is set to release its earnings on Thursday, August 7, 2025. In the past, Eli Lilly's stock has displayed a pattern of negative one-day returns following earnings announcements.
Insights Into Lilly (LLY) Q2: Wall Street Projections for Key Metrics
Get a deeper insight into the potential performance of Lilly (LLY) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Should You Buy, Sell or Hold Lilly Stock Ahead of Q2 Earnings?
LLY eyes Q2 growth on Mounjaro and Zepbound momentum, but pricing pressure and rising competition test its edge.
Trim Your AI Stocks And Buy Eli Lilly
AI and semiconductor stocks are too expensive right now. Don't buy them now, trim your high-tech positions, and buy healthcare stocks like Eli Lilly and Company. LLY is a hyper-growth-at-a-reasonable-price play. A 30% 12-month return is reasonable to anticipate. It is not too early to buy healthcare stocks; it will just require patience. I'd rather leave the party first and miss the traffic than move with the crowd.
Eli Lilly: The Worst May Be Already Over (Earnings Preview)
Eli Lilly (LLY) is set to report Q2 2025 earnings on August 7, with consensus expecting $14.4 billion in revenue and $5.56 EPS, up 30-42% YoY. Analysts expect continued volume-driven revenue and margin expansion, with consensus seeing EPS and sales growth well above industry averages through 2026. LLY's Q1 saw 45% revenue growth but a minor EPS miss due to IPR&D charges; management reaffirmed full-year guidance, and volume growth is expected to offset price erosion.
Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth
Lilly (LLY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Elli Lilly Weight-Loss Drug Makes Cardio Advance. More Bad News for Novo Nordisk.
A Lilly study showed Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with the older drug Trulicity.
